Table 4 Ongoing clinical trials evaluating the combination of TAM-targeted therapy and ICIs
Strategies | Agent | Cancer type | Combination partners | Clinical trials registry | Clinical phase |
|---|---|---|---|---|---|
Macrophages recruitment inhibition | CSF1/CSF1R inhibitor | Â | Â | Â | Â |
| Â | Vimseltinib (DCC-3014) | Sarcoma | Avelumab | NCT04242238 | I (Active) |
|  | Axatilimab (SNDX6352) | Solid tumor | Retifanlimab + chemotherapy | NCT06320405 | I/II (Recruiting) |
| Â | Â | HL | Nivolumab | NCT05723055 | II (Recruiting) |
| Â | Â | TNBC | Pembrolizumab | NCT05491226 | II (Recruiting) |
|  | Cabiralizumab | TNBC | Nivolumab + chemotherapy | NCT04331067 | I/II (Active) |
| Â | Â | HCC | Nivolumab | NCT04050462 | II (Active) |
Macrophages elimination | Trabectedin | Sarcoma | Nivolumab | NCT03886311 | II (Recruiting) |
Macrophages reprogram | PI3Kg inhibitor | Â | Â | Â | Â |
|  | IPI-549 | TNBC, RCC | Atezolizumab + bevacizumab /nab-paclitaxel | NCT03961698 | II (Active) |
| Â | BYL719 | Solid tumor | Atezolizumab/ ipilimumab/ nivolumab | NCT04591431 | II (Active) |
| Â | Duvelisib (IPI-145) | Melanoma | Nivolumab | NCT04688658 | I/II (Active) |
| Â | STAT3 inhibitor | Â | Â | Â | Â |
|  | AZD9150 | NSCLC | Durvalumab + chemotherapy | NCT03421353 | I (Active) |
|  |  | NSCLC | Durvalumab + danvatirsen | NCT03819465 | I (Active) |
| Â | Â | Bladder cancer | Durvalumab | NCT02546661 | I (Active) |
|  |  | Solid tumors, HNSC | Durvalumab + tremelimumab | NCT02499328 | I/II (Active) |
| Â | Â | NSCLC | Durvalumab | NCT03334617 | II (Active) |
|  |  | PCA, NSCLC, CRC | Durvalumab + danvatirsen | NCT02983578 | II (Active) |
| Â | TLR agonist | Â | Â | Â | Â |
| Â | MGN1703 | Solid tumor | Ipilimumab | NCT02668770 | I (Active) |
| Â | CMP-001 | Lymphoma | Pembrolizumab | NCT03983668 | I/II (Active) |
| Â | TransCon TLR7/8 Agonist | Solid tumor | Pembrolizumab | NCT04799054 | I/II (Active) |
| Â | TransCon TLR7/8 Agonist | HNSC | Pembrolizumab | NCT05980598 | II (Active) |
|  | BDC-1001 | HER2 + Solid tumor | Nivolumab | NCT04278144 | I/II (Active) |
| Â | CD40 agonist antibody | Â | Â | Â | Â |
|  | Selicrelumab (RO7009789) | PDAC | Atezolizumab + chemotherapy | NCT03193190 | I/II (Active) |
|  |  | BC | Atezolizumab + bevacizumab | NCT03424005 | I/II (Recruiting) |
|  | CDX-1140 | Solid tumor | TCR-T + pembrolizumab | NCT04520711 | I (Active) |
| Â | APX005M | Melanoma | Pembrolizumab | NCT02706353 | I/II (Active) |
|  |  | Melanoma, RCC | Nivolumab + Ipilimumab | NCT04495257 | I (Active) |
|  |  | PC | Zimberelimab + domvanalimab | NCT05419479 | I/II (Recruiting) |
| Â | Â | PC, CRC | Pembrolizumab | NCT02600949 | I (Recruiting) |
|  |  | Ovarian cancer | Pembrolizumab + bevacizumab | NCT05231122 | I/II (Recruiting) |
| Â | IL-4R inhibitor | Â | Â | Â | Â |
| Â | Dupilumab | NSCLC | Cemiplimab | NCT06088771 | I/II (Recruiting) |
| Â | IL-6/IL-6R inhibitor | Â | Â | Â | Â |
|  | Tocilizumab | Melanoma | Ipilimumab + Nivolumab | NCT03999749 | II (Active) |
|  |  | Melanoma, Urothelial carcinoma, NSCLC | Ipilimumab + Nivolumab | NCT04940299 | II (Active) |
| Â | Â | PCA | Atezolizumab | NCT03821246 | II (Active) |
| Â | Â | GBM | Atezolizumab | NCT04729959 | II (Active) |
|  |  | PDAC | Atezolizumab + Gemcitabine + Nab-Paclitaxel | NCT03193190 | I/II (Active) |
| Â | Â | NSCLC | Atezolizumab | NCT04691817 | I/II (Recruiting) |
|  |  | Liver cancer | Atezolizumab + Bevacizumab | NCT04524871 | I/II (Recruiting) |
| Â | Â | HNSCC | Atezolizumab | NCT03708224 | II (Recruiting) |
| Â | Siltuximab | Solid tumor | Anti-PD-L1 | NCT06470971 | II (Recruiting) |
|  | Sarilumab | Melanoma | Ipilimumab + Nivolumab/Relatlimab | NCT05428007 | I/II (Recruiting) |
| Â | Â | NSCLC | Cemiplimab | NCT05704634 | I (Recruiting) |
|  |  | Ovarian cancer | REGN4018 + cemiplimab | NCT03564340 | I/II (Recruiting) |
| Â | IL-8/IL-8R inhibitor | Â | Â | Â | Â |
| Â | BMS-986,253 | HCC | Nivolumab | NCT04050462 | II (Active) |
| Â | Â | NSCLC, HCC | Nivolumab | NCT04123379 | II (Active) |
|  |  | Solid tumor | Ipilimumab + Nivolumab | NCT03400332 | I/II (Active) |
| Â | Â | Solid tumor Melanoma | Nivolumab | NCT04572451 | I (Recruiting) |
| Â | Â | HNSCC | Nivolumab | NCT04848116 | II (Recruiting) |
| Â | Â | PDAC | Nivolumab | NCT02451982 | II (Recruiting) |
| Â | Â | CRC | Nivolumab | NCT03026140 | II (Recruiting) |
| Â | AZD5069 | Solid tumor HNSCC | MEDI4736 | NCT02499328 | I/II (Active) |
Macrophages phagocytosis | AntiCD47 antibody | Â | Â | Â | Â |
| Â | Magrolimab (Hu5F9-G4) | HL | Pembrolizumab | NCT04788043 | II (Active) |
| Â | Â | Urothelial carcinoma | Atezolizumab | NCT03869190 | I/II (Recruiting) |
|  | Golcadomide (CC-9002) | Follicular lymphoma | Nivolumab + rituximab | NCT05788081 | II (Recruiting) |
| Â | Evorpacept (ALX148) | Solid tumors, lymphoma | Pembrolizumab | NCT03013218 | I (Active) |
|  |  | CRC | Cetuximab + pembrolizumab | NCT05167409 | II (Active) |
| Â | Â | HNSC | Pembrolizumab | NCT04675294 | II (Active) |
| Â | Â | HNSC | Pembrolizumab | NCT04675333 | II (Active) |
|  |  | Ovarian cancer | Pembrolizumab + doxorubicin | NCT05467670 | II (Recruiting) |
| Â | SIRP- Fc mAb | Â | Â | Â | Â |
| Â | TTI-621 | DLBCL | Pembrolizumab | NCT05507541 | II (Recruiting) |
| Â | AntiCD47/PD-1 antibody | Â | Â | Â | Â |
| Â | HX009 | Solid tumors | None | NCT05731752 | I (Active) |
| Â | Â | Lymphoma | None | NCT05189093 | I/II (Recruiting) |